Early research (Phase 1)Ended earlyNCT02335814
What this trial is testing
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Who this might be right for
Acute Myeloid Leukemia
RAPT Therapeutics, Inc., a member of the GSK plc group of companies 51